Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Jan;30(1):102-110.
doi: 10.1002/jhbp.1219. Epub 2022 Aug 9.

Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)

Tatsuya Ioka  1   2 , Masashi Kanai  3 , Shogo Kobayashi  4 , Daisuke Sakai  5 , Hidetoshi Eguchi  6 , Hideo Baba  7 , Satoru Seo  8 , Akinobu Taketomi  9 , Tadatoshi Takayama  10 , Hiroki Yamaue  11 , Masahiro Takahashi  12 , Masayuki Sho  13 , Keiko Kamei  14 , Jiro Fujimoto  15 , Masanori Toyoda  16 , Junzo Shimizu  17 , Takuma Goto  18 , Yoshitaro Shindo  19 , Kenichi Yoshimura  20 , Etsuro Hatano  8 , Hiroaki Nagano  19 ; Kansai Hepatobiliary Oncology Group (KHBO)
Affiliations
Clinical Trial

Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)

Tatsuya Ioka et al. J Hepatobiliary Pancreat Sci. 2023 Jan.

Abstract

Background: Gemcitabine/cisplatin (GC) combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). No randomized clinical trials have been able to demonstrate the survival benefit over GC during the past decade. In our previous phase II trial, adding S-1 to GC (GCS) showed promising efficacy and we aimed to determine whether GCS could improve overall survival compared with GC for patients with advanced BTC.

Methods: We performed a mulitcenter, randomized phase III trial across 39 centers. Enrolled patients were randomly allocated (1:1) to either the GCS or GC arm. The GCS regimen comprised gemcitabine (1000 mg/m2 ) and cisplatin (25 mg/m2 ) infusion on day 1 and 80 mg/m2 of S-1 on days 1-7 every 2 weeks. The primary endpoint was overall survival (OS) and the secondary endpoints were progression-free survival (PFS), response rate (RR), and adverse events (AEs). This study is registered with Clinical trial identification: NCT02182778.

Results: Between July 2014 and February 2016, 246 patients were enrolled. The median OS and 1-year OS rate were 13.5 months and 59.4% in the GCS arm and 12.6 months and 53.7% in the GC arm, respectively (hazard ratio [HR] 0.79, 90% confidence interval [CI]: 0.628-0.996; P = .046 [stratified log-rank test]). Median PFS was 7.4 months in the GCS arm and 5.5 months in the GC arm (HR 0.75, 95% CI: 0.577-0.970; P = .015). RR was 41.5% in the GCS arm and 15.0% in the GC arm. Grade 3 or worse AEs did not show significant differences between the two arms.

Conclusions: GCS is the first regimen which demonstrated survival benefits as well as higher RR over GC in a randomized phase III trial and could be the new first-line standard chemotherapy for advanced BTC. To exploit the advantage of its high RR, GCS is now tested in the neoadjuvant setting in a randomized phase III trial for potentially resectable BTC.

Keywords: S-1; biliary tract cancer; cisplatin; gemcitabine.

PubMed Disclaimer

Conflict of interest statement

TI has received personal fees from Incyte, Chugai, Yakult Honsha, Taiho Pharmaceutical, Ono Pharm, Servier, Daiichi Sankyo, Nihon Zouki, Eli‐Lilly, Otsuka, Novartis, AstraZeneca and Abbott. MK has received personal fees from Chugai. MT has received personal fees from Ono. KY has received personal fees from Ohara, Nihon‐Shinyaku, Sysmex, Chugai Pharma, Eli‐Lilly, Astra Zeneca, Otsuka, Novartis, Eisai, Nihon‐Kayaku, Boehringer Ingelheim, Taiho and Pfizer. EH has received personal fees from Eli‐Lilly and Taiho. The other authors declare that they have no competing interest.

Figures

FIGURE 1
FIGURE 1
Schematic outline of the design parameters, metrics and observed quantities of the trial.
FIGURE 2
FIGURE 2
Overall survival of patients in the GC (blue) and GCS (red) arms of the study.
FIGURE 3
FIGURE 3
Progression‐free survival of patients in the GC (blue) and GCS (red) arms of the study.
FIGURE 4
FIGURE 4
Subgroup analyses of overall survival and progression‐free survival.
See this image and copyright information in PMC

References

    1. Lim H, Seo DW, Park DH, Lee SS, Lee SK, Kim MH, et al. Prognostic factors in patients with gallbladder cancer after surgical resection: analysis of 279 operated patients. J Clin Gastroenterol. 2013;47(5):443–8. - PubMed
    1. Matsukuma S, Tokumitsu Y, Shindo Y, Matsui H, Nagano H. Essential updates to the surgical treatment of biliary tract cancer. Ann Gastroenterol Surg. 2019;3(4):378–89. - PMC - PubMed
    1. Marcano‐Bonilla L, Mohamed EA, Mounajjed T, Roberts LR. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. Chin Clin Oncol. 2016;5(5):61. - PubMed
    1. Wakai T, Nagahashi M, Shimada Y, Prasoon P, Sakata J. Genetic analysis in the clinical management of biliary tract cancer. Ann Gastroenterol Surg. 2020;4(4):316–23. - PMC - PubMed
    1. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. - PubMed

Publication types

MeSH terms

Associated data

Grants and funding